Skip to main content
Caplight Logo









ConSynance Therapeutics

ConSynance Therapeutics

Private
Rensselaer, New YorkHealthcare & Life Scienceshttps://www.consynance.com/

Last Round

Grant

Apr 15, 2026

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ConSynance Therapeutics is a biopharmaceutical company that develops treatments for central nervous system diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

Prader-Willi SyndromePWSrare CNS disordershyperphagia treatmentsmall molecule therapeuticsorphan drugsclinical-stage biotechtriple monoamine reuptake inhibitorCNS drugsneuropsychiatric drugshypothalamic obesityRare Pediatric Disease DesignationRPDDPriority Review VoucherPRVMCHR1 antagonist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ConSynance Therapeutics Comparables

Compare ConSynance Therapeutics with similar companies based on industry and business-model similarity.

ConSynance Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Saniona AB
78%
Aardark Therapeutics
77%
Relmada Therapeutics
74%

ConSynance Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 15, 2026
DivestitureAug 9, 2021

Key People

Founding team and executive leadership

Shuang Liu

CEO and Founder

Founding Team

ConSynance Therapeutics Investors

Notable investors and investment history

ConSynance Therapeutics investors
InvestorRounds
Foundation for Prader-Willi ResearchGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Received grant from Foundation for Prader-Willi Research.

  • Mar 1, 2026

    Monthly visitors grew 570% MoM to 1.5K.

ConSynance Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ConSynance Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ConSynance Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRensselaer, New York
Employee Range3
Year Founded2015
Last FundingApr 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?